SOURCES SOUGHT
R -- Project Health Economist (Botswana)
- Notice Date
- 8/3/2009
- Notice Type
- Sources Sought
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- 2009-Q-11627
- Point of Contact
- Terren J. Grimble, Phone: 770-488-2487, Rafael A. Aviles, Phone: 770-488-2805
- E-Mail Address
-
TGrimble@cdc.gov, raviles@cdc.gov
(TGrimble@cdc.gov, raviles@cdc.gov)
- Small Business Set-Aside
- N/A
- Description
- Notice of Intent Ref# 2009-Q-11627 The Centers for Disease Control and Prevention, Division of Tuberculosis Elimination, intents to award a sole source, firm fixed price contract, in accordance with FAR Part 13 and FAR Part 6.302(1), using simplified acquisition procedures, to BaseCase GmbH, ATC Steinhof 4.OG, Bahnhofstrasse 28, CH-6300 Zug, Switzerland for a period of 3 months. The contractor will perform a formal cost-effectiveness analysis from the societal perspective to establish the costs and health effects of the chest x-ray (CXR) component of the screening algorithm for active tuberculosis (TB), that is currently used by the isoniazid preventive therapy (IPT) trial in Botswana and write a report with recommendations to BOTUSA, and submit a paper of this analysis to a high impact peer-reviewed journal. This study will inform policy makers on the incremental costs and health effects of the addition of CXR screening to an IPT screening algorithm. Additional screening with CXR at the end of the current IPT screening algorithm is expected to result in a higher number of true positive findings of active TB. Excluding more patients with active TB (CXR true positives) from an IPT program will lead to cost savings within the IPT program and also lower rates of isoniazid (INH) resistant TB. Subsequent treatment of the additional active TB cases detected will result in lower morbidity and mortality. However, CXR screening also results in CXR false positives. Excluding these patients will lead to cost savings within IPT, but is also expected to lead to a higher incidence of TB (because of not being on IPT), that will in turn result in higher morbidity and mortality. Another consequence is that exclusion of patients from the IPT program, will decrease the probability of getting access to HIV care. Not starting IPT will also prevent INH adverse events. BaseCase GmbH is a health economics consultancy firm, specialized in the field of infectious diseases. A cooperation with University of Groningen, Groningen Research Institute of Pharmacy (GRIP), Groningen, Netherlands has existed since 2003, and has been strengthened in recent years with joint publications on the cost-effectiveness of Tipranavir (a protease inhibitor used in salvage HAART), the cost of HIV/AIDS care in Italy, universal infant pneumococcal vaccination in the Netherlands, and MRSA screening at hospital admission [2, 12-14]. An economic evaluation of the national IPT program of Botswana as part of the IPT evaluation panel has recently been performed. The overview of IPT resource use items produced as part of this evaluation will serve as a starting point for this study. No Request for Quotes (RFQ) will be issued based upon this Notice of Intent. Any interested companies are welcome to submit there credentials and ability to provide the services, via e-mail, ibi9@cdc.gov. Include reference number (2009-Q-11627). Send responses by Friday August 7, 2009. This advertisement ends in 5 days accordance with FAR 5.203 (A) (1).
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/2009-Q-11627/listing.html)
- Record
- SN01897617-W 20090805/090804000328-70748ce02e9b06de26894733aaa00bbe (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |